Literature DB >> 12186305

The effect of scopolamine in older rabbits tested in the 750 ms delay eyeblink classical conditioning procedure.

Diana S Woodruff-Pak1, John T Green, Jonathan T Pak, Boris Heifets, Michelle H Pak.   

Abstract

We investigated the effect of several doses of scopolamine in older rabbits that were trained for 20 days in the 750 ms delay eyeblink classical conditioning procedure. Our aim was to determine if the scopolamine-injected older rabbit would be a useful model for testing drugs for cognition enhancement in Alzheimer's disease (AD). A total of 39 rabbits with a mean age of 31 months received classical eyeblink conditioning with daily injections of 0.25, 0.75, or 1.5 mg/kg scopolamine hydrobromide or sterile saline vehicle. Doses of 0.75 and 1.5 mg/kg scopolamine significantly impaired acquisition, whereas acquisition was not significantly impaired with 0.25 mg/kg scopolamine. Results exhibit parallels in performance on delay eyeblink classical conditioning between scopolamine-treated older rabbits and human patients diagnosed with AD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12186305     DOI: 10.1007/bf02688823

Source DB:  PubMed          Journal:  Integr Physiol Behav Sci        ISSN: 1053-881X


  40 in total

1.  Single-unit analysis of different hippocampal cell types during classical conditioning of rabbit nictitating membrane response.

Authors:  T W Berger; P C Rinaldi; D J Weisz; R F Thompson
Journal:  J Neurophysiol       Date:  1983-11       Impact factor: 2.714

2.  Altered activity in the hippocampus is more detrimental to classical conditioning than removing the structure.

Authors:  P R Solomon; S D Solomon; E V Schaaf; H E Perry
Journal:  Science       Date:  1983-04-15       Impact factor: 47.728

3.  Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists.

Authors:  T G Beach; D G Walker; P E Potter; L I Sue; A Fisher
Journal:  Brain Res       Date:  2001-06-29       Impact factor: 3.252

4.  Eyeblink conditioning discriminates Alzheimer's patients from non-demented aged.

Authors:  D S Woodruff-Pak; R G Finkbiner; D K Sasse
Journal:  Neuroreport       Date:  1990-09       Impact factor: 1.837

Review 5.  Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.

Authors:  A Fisher
Journal:  Jpn J Pharmacol       Date:  2000-10

6.  Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology.

Authors:  E K Perry; C M Morris; J A Court; A Cheng; A F Fairbairn; I G McKeith; D Irving; A Brown; R H Perry
Journal:  Neuroscience       Date:  1995-01       Impact factor: 3.590

7.  Topographic analysis of the innervation of the rat neocortex and hippocampus by the basal forebrain cholinergic system.

Authors:  M McKinney; J T Coyle; J C Hedreen
Journal:  J Comp Neurol       Date:  1983-06-10       Impact factor: 3.215

8.  Scopolamine disruption of septo-hippocampal activity and classical conditioning.

Authors:  A T Salvatierra; S D Berry
Journal:  Behav Neurosci       Date:  1989-08       Impact factor: 1.912

9.  Effects of scopolamine and methylscopolamine on classical conditioning of the rabbit nictitating membrane response.

Authors:  J A Harvey; I Gormezano; V A Cool-Hauser
Journal:  J Pharmacol Exp Ther       Date:  1983-04       Impact factor: 4.030

10.  Direct autoradiographic determination of M1 and M2 muscarinic acetylcholine receptor distribution in the rat brain: relation to cholinergic nuclei and projections.

Authors:  D G Spencer; E Horváth; J Traber
Journal:  Brain Res       Date:  1986-08-13       Impact factor: 3.252

View more
  2 in total

1.  Acetylcholine receptor and behavioral deficits in mice lacking apolipoprotein E.

Authors:  Jessica A Siegel; Theodore S Benice; Peter Van Meer; Byung S Park; Jacob Raber
Journal:  Neurobiol Aging       Date:  2009-01-28       Impact factor: 4.673

Review 2.  Neurological and neurobehavioral assessment of experimental subarachnoid hemorrhage.

Authors:  Hyojin Jeon; Jinglu Ai; Mohamed Sabri; Asma Tariq; Xueyuan Shang; Gang Chen; R Loch Macdonald
Journal:  BMC Neurosci       Date:  2009-08-25       Impact factor: 3.288

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.